Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cassava Sciences Inc
(NQ:
SAVA
)
29.45
-0.23 (-0.77%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cassava Sciences Inc
< Previous
1
2
3
4
5
6
7
8
9
...
32
33
Next >
Cassava ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cassava Sciences, Inc. and Encourages Investors to Contact the Firm
February 05, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
February 05, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
February 05, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Is There Any Hope for Cassava Sciences Stock?
February 03, 2024
Battered by controversy, this company will need to show real results to prosper.
Via
The Motley Fool
(SAVA) - Analyzing Cassava Sciences's Short Interest
January 29, 2024
Via
Benzinga
1 Big Red Flag to Fear When a Stock Is Down
October 31, 2023
Playing the blame game does not make for an effective turnaround strategy.
Via
The Motley Fool
3 Biotech Stocks to Sell in January Before They Crash and Burn
January 25, 2024
The biotech industry is one of the most profitable though risky at the same time. Here are three biotech stocks to sell.
Via
InvestorPlace
Cassava Sciences Stock Continues Showing Rising Relative Strength
January 16, 2024
Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level.
Via
Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
January 15, 2024
Via
Benzinga
Portfolio Protection: 7 Risky Stocks to Drop Right Now
January 12, 2024
Ahead of further or unforeseen challenges, if you own any of these seven risky stocks, now's the time to bail.
Via
InvestorPlace
New SAVAW Warrants Are Trading After Cassava Sciences’ Distribution
January 05, 2024
Following a distribution, investors in Cassava Sciences and SAVA stock now have some warrants to factor into their models today.
Via
InvestorPlace
Why Cassava Sciences Stock Surged Today
October 25, 2023
Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading higher after the company announced MRI data suggested simufilam is not associated with amyloid-
Via
Benzinga
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
January 05, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street
December 26, 2023
Wall Street analysts foresee up to 316% upside in three fast-paced companies in the new year.
Via
The Motley Fool
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
December 21, 2023
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings.
Via
Benzinga
Paychex Reports Downbeat Sales, Joins BlackBerry And Other Big Stocks Moving Lower On Thursday
December 21, 2023
U.S. stocks traded higher, with the Dow Jones index gaining around 200 points on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Cassava Sciences Stock Zoomed 21% Higher This Week
December 15, 2023
The company has chosen an offbeat way to keep its investors sweet.
Via
The Motley Fool
Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days
December 13, 2023
Cassava Sciences sees its Relative Strength Rating reach the 80-plus level.
Via
Investor's Business Daily
Why Is Cassava Sciences (SAVA) Stock Up 15% Today?
December 12, 2023
Although Cassava Sciences’ issuance of warrants presents risks, the underlying Phase 3 trial support boosted SAVA stock.
Via
InvestorPlace
Blue Bird Posts Upbeat Results, Joins Oil-Dri Corporation of America, Eagle Bulk Shipping And Other Big Stocks Moving Higher On Tuesday
December 12, 2023
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders
December 12, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
What's Going On With Cassava Sciences Stock?
December 11, 2023
Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading higher Monday on continued upward momentum. The stock has gained more than 20% over than last five days. What To Know:
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
December 11, 2023
Via
Benzinga
High short interest stocks: this popular trend is re-emerging
December 11, 2023
Renewed optimism has led to higher risk tolerance in stocks, which has brought back a popular trend: Stocks with high short interest are gaining popularity
Via
MarketBeat
Topics
ETFs
Why Cassava Sciences Stock Soared Today
December 08, 2023
Investors cheered the arrival of a trio of new board members.
Via
The Motley Fool
Cassava Sciences Appoints Three New Members to its Board of Directors
December 07, 2023
Dr. Nicaise, Mr. Gravier and Mr. Anderson have years of experience in drug development, healthcare M&A and working with the U.S. Government
From
Cassava Sciences, Inc.
Via
GlobeNewswire
7 High-Risk, High-Reward Stocks for the Extreme Contrarian
November 14, 2023
While most folks should stick on the established road, these stock picks for contrarian investors might tempt the intrepid.
Via
InvestorPlace
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
November 07, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
November 06, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)
October 25, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
32
33
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.